Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. - Wikidata - awgldk - TriplyDB

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

http://www.wikidata.org/entity/Q33814903

about

Human recombinant activated protein C for severe sepsis Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients Human recombinant activated protein C for severe sepsis Biomarkers and molecular probes for cell death imaging and targeted therapeutics Targeting HMGB1 in inflammation Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats.High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes High-mobility group box-1 induces proinflammatory cytokines production of Kupffer cells through TLRs-dependent signaling pathway after burn injury HMGB1 in health and disease.The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis.EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages High mobility group box 1 induced human lung myofibroblasts differentiation and enhanced migration by activation of MMP-9.Sepsis: Something old, something new, and a systems view.Presence of preexisting antibodies mediates survival in sepsis.Anti-inflammatory role of fetuin-A in injury and infection.Impact of Histone H1 on the Progression of Allergic Rhinitis and Its Suppression by Neutralizing Antibody in Mice Ethyl pyruvate induces heme oxygenase-1 through p38 mitogen-activated protein kinase activation by depletion of glutathione in RAW 264.7 cells and improves survival in septic animals Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1 Levosimendan for Septic Myocardial Dysfunction: Not Yet Ready for Prime Time High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma.Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells.Nuclear antigens and auto/alloantibody responses: friend or foe in transplant immunology.Plasma HMGB-1 and Nucleosome Concentrations in Horses with Colic and Healthy Horses Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis.CD14 contributes to warm hepatic ischemia-reperfusion injury in mice Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers.Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand.Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.High-mobility group box 1, oxidative stress, and disease.Role of high mobility group box 1 in inflammatory disease: focus on sepsis.Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRα(+) mesenchymal cells from bone marrow.Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock.Sterile Neuroinflammation and Strategies for Therapeutic Intervention Anti-septic effects of pelargonidin on HMGB1-induced responses in vitro and in vivo.

P2860

Q24201123-DB97B666-9F33-4CCF-A3C4-A131F7944155 Q24202128-FD83ACAE-4734-4B39-AA67-FE3D871EB174 Q24235181-D807FC41-54EC-4866-993A-36CCD43782C2 Q26866387-EA7A3B9C-4235-4968-98AF-E152CB03A9D4 Q28266138-AECCE6C5-DB21-404F-ADCE-97E4DB6D1226 Q28533928-28651826-A0D6-4082-BAF2-FCD0E3FEAB40 Q28658232-FEF7FDC8-C52A-472B-BB6B-36431B916020 Q28742970-69CA39D9-5141-4101-8733-5954A26B1F17 Q33551765-B0EF02C9-E860-48C8-97CB-E187B19C603E Q33814947-CDBAABE7-DB8C-4204-821B-E455C198924D Q33836853-303B82D0-33BB-41EA-BC9F-C0160BA74718 Q34315899-E3E71DB2-E39E-459E-8DE0-C7C18B6B513F Q34500594-7D9CB471-5466-4C5A-B431-DBAC204978E5 Q34622835-7CBCD19C-425A-44BB-B244-E8653F3FE9E2 Q34769562-DF41D2A0-88B2-441C-8670-136805AC0A42 Q34770544-65E17FD0-09AE-4650-BEDD-6B2F579FF4DE Q35096279-ECAC76EB-9B30-4103-B13D-624DEB52034A Q35500956-67BABE75-7765-4764-9192-BE9CAD5928E5 Q35621514-DAFDFDE5-FC26-4F55-ADD0-AD59F2C3785F Q35951563-A92B5F34-B02F-4F40-BA72-EDEA19A0F40E Q35992370-C0B9273A-6C1E-4BD4-A26B-7445914E99AB Q36084464-4A2D8886-7122-4ADF-92C7-5ACCB50D9C57 Q36165681-8B394EBC-12CD-4D4E-8705-0A83BD90C28F Q36175405-CA29F265-8CCB-4CAB-8E1C-FA0895819970 Q36254446-2584E3AE-7CA1-42C6-86DF-BB90204BFF00 Q36357435-69638B91-1E78-41A7-8473-7075DED59BEE Q36438398-339E927F-A153-4789-9BF4-07881F0A9C13 Q36830358-7D82C483-D35C-4C0E-91E4-D300CD90B628 Q37020379-B2F3A3B4-14EC-4371-9DC1-792EE4BC272F Q37032209-EE9F5E86-2C45-46AE-8BBC-CFDEC239DF2D Q37034816-8630EBD9-4DE3-4004-BAFD-D5BB32B942D4 Q37254575-8B25259B-A8FB-4D88-A675-CA6DE0B270A2 Q37347450-8AF51010-5A64-4856-8B72-BAFCBB334397 Q37800819-ECDBBB0E-45FA-443C-9DA7-52E646F2426C Q37802381-60CB305D-E9F2-429D-A28E-7E954C2EDB81 Q38051217-5C82BA4A-D9EE-4DF9-8906-3DC177E45137 Q38998975-E61D9595-0F19-4731-B276-7E1292917616 Q39103864-CDC1DDF6-CA6B-4AF8-ACDB-F3428082B0C8 Q39105980-A8313C48-5CF7-496A-AB27-75FB28209BD6 Q39252077-8BBC2F76-9AA6-40EE-9365-5B35F9ED21F2

P2860

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

http://www.wikidata.org/entity/Q33814903

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@ast

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@en

type

label

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@ast

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@en

prefLabel

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@ast

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@en

P1433

Q33814903-4FE0F48B-EAB3-40FA-81B6-D364B0CA05D7

P1476

Q33814903-306E552C-FB0F-458C-A734-13B8A8501A74

P2093

Q33814903-821E55DB-F6B7-4914-A2A4-908BD8BB48B0

Q33814903-B2A8B5FC-BEAC-4B4B-9A95-45C978921E79

P2860

Q33814903-017ECF41-5398-4B3F-A3BC-188D99653B97

Q33814903-01FADAD7-D9D1-4241-B8B8-14304ED4A980

Q33814903-025EED8B-A623-4062-8CD4-286A183D3AB4

Q33814903-04F77A05-0AE8-4CC4-BBD2-58468543E40A

Q33814903-0DB05094-6924-473E-BE7B-79769262AE1A

Q33814903-112DE50E-105B-4DFB-87F6-E35A8C59F89B

Q33814903-1484AAB2-E039-456F-8917-95A77917B0CE

Q33814903-14919E91-7452-4F1B-89CC-715B9146EB0C

Q33814903-15E015C8-EF9C-43E1-96C0-84ABCB782878

Q33814903-18569158-5E07-4B18-8899-6BD9C326F7A2

P304

Q33814903-0AB6C6A4-8A85-4F3A-A121-9F892C2FBEA8

P31

Q33814903-1B279F5B-BCC5-4B31-8EA5-C986A4E688CB

P356

Q33814903-85BA5F1B-C9EC-43E9-B112-6D0BC122D063

P433

Q33814903-BE54AEF6-C87A-4BAE-AB4D-A459AE52B0A3

P478

Q33814903-72B93535-A424-42EA-A8B1-708ED53506E4

P50

Q33814903-3A7344C2-1620-4986-A252-8C85DF0A91ED

P577

Q33814903-F5517C6F-B606-49C5-A0B0-E79127EF680F

P698

Q33814903-40E92B04-4E8B-474B-B060-3DF621D69B51

P921

Q33814903-024F277B-47F7-4D85-88FF-A2D95AA96115

P932

Q33814903-8AA38172-50D7-4509-ABBA-40C8209BA17A

P356

SHK.0B013E3181A551BD

P1433

P1476

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

@en

P2093

Andrew E Sama

http://www.w3.org/2001/XMLSchema#string

Mary F Ward

http://www.w3.org/2001/XMLSchema#string

P2860

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

A Toll-like receptor recognizes bacterial DNA

Structural basis for the proinflammatory cytokine activity of high mobility group box 1

Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein

The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway

Toll-like receptor signalling

A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1

High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

P304

348-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SHK.0B013E3181A551BD

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19333143

http://www.w3.org/2001/XMLSchema#string

P921

P932

2860725

http://www.w3.org/2001/XMLSchema#string